Advertisement
Journal Home
Search for

Volume 36, Issue 1, Pages 33-42 (February 2010)


View previous. 6 of 12 View next.

Novel therapeutic approaches to the treatment of metastatic breast cancer

Yolanda FernándezaCorresponding Author Informationemail address, Juan Cuevab, Andrés G. Palomoc, Manuel Ramosd, Ana de Juane, Lourdes Calvof, Jesús García-Matag, Paula García-Teijidoa, Ignacio Peláezh, Laura García-Estévezi

Received 2 July 2009; received in revised form 30 September 2009; accepted 2 October 2009. published online 02 November 2009.

Abstract 

Metastatic breast cancer is ultimately an incurable disease, although recent data have shown that its incidence is decreasing and that patients with metastatic breast cancer live longer. This improvement in survival seems to be linked with the introduction of new therapeutic agents, novel combinations of existing therapies and targeted therapies. Our increasing understanding of the molecular biology of metastatic disease has allowed the development of therapies aimed at specific molecular targets. Some of these have already been approved for the treatment of metastatic breast cancer in combination with cytotoxics, and others have shown promising results regarding disease-free survival, overall response rates and time to disease progression. Given the enormous amount of information about drug discovery in cancer, it is important to be familiar with the present state of the treatment of metastatic breast cancer. The purpose of this review is to provide an update on the development of some of the most promising novel agents and treatment strategies in metastatic breast cancer.

a Hospital Universitario Central de Asturias, Oviedo, Spain

b Complexo Hospitalario Universitario de Santiago, A Coruña, Spain

c Hospital de León, León, Spain

d Centro Oncológico Regional, A Coruña, Spain

e Hospital Marqués de Valdecilla, Santander, Spain

f Complexo Hospitalario Universitario Juan Canalejo, A Coruña, Spain

g Complexo Hospitalario de Ourense, Ourense, Spain

h Hospital de Cabueñes, Gijón, Spain

i Centro Integral Oncológico “Clara Campal”, Madrid, Spain

Corresponding Author InformationCorresponding author. Address: Medical Oncology Service, Hospital Universitario Central de Asturias, Calle Celestino Villamil, s/n. 33006-Oviedo, Spain. Tel.: +34 985 108 000; fax: +34 985 108 015.

PII: S0305-7372(09)00142-X

doi:10.1016/j.ctrv.2009.10.001


View previous. 6 of 12 View next.

Advertisement